A United Arab Emirates company is nearing the end of Phase III clinical trials of a Chinese COVID-19 vaccine and hopes to manufacture it next year, a representative said. The vaccine uses an inactivated virus; a well-known technology which has been used against diseases such as influenza and measles. Results analysis and publication will happen in around two months, Koshy said. He said G42 has distribution and manufacturing agreements with Sinopharm and hopes to provide the UAE and other regional states with the vaccine, especially those that participated in the trial. The UAE has a high per capita rate of COVID-19 tests, having carried out more than 10 million tests in a population of around 9.9 million, the government statistics authority says.

Source: dna October 08, 2020 16:47 UTC